BenFox

Like many medical-device companies, Boston Scientific has in recent years begun investing heavily in emerging economies such as China, where a health-care overhaul has expanded access to services and boosted demand for pharmaceuticals and medical devices.

Device firms hope those investments can offset sales pressure at home and in Europe, where sales have slowed.

Boston Scientific reported a profit of $108 million, or eight cents a share, up from $60 million, or four cents a share, a year earlier. Excluding restructuring and litigation-related charges and other items, earnings rose to 21 cents from 18 cents.

Net sales edged up 0.9% to $1.84 billion.

Boston Scientific expected an adjusted profit of 18 cents to 20 cents a share and revenue of $1.78 billion to $1.83 billion.

For the new year, the company expects to post adjusted earnings of 75 cents to 80 cents a share on revenue of $7.3 billion to $7.5 billion. Analysts surveyed by Thomson Reuters estimated revenue of $7.41 billion.

Boston Scientific also predicted a first-quarter adjusted profit of 16 cents to 18 cents a share and revenue of $1.755 billion to $1.805 billion. Market estimates were for revenue of $1.8 billion.

Shares closed Monday at $13.01 and were up 1.8% premarket. As of the close, the stock was up 8.2 % so far this year.

Intraday Data provided by SIX Financial Information and subject to terms of use.
Historical and current end-of-day data provided by SIX Financial Information. Intraday data
delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc.
All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More
information on NASDAQ traded symbols and their current financial status. Intraday
data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM)
from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is
at least 60-minutes delayed. All quotes are in local exchange time.